J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under ...

The news keeps getting better for the new GLP-1 weight-loss drugs fromEli Lilly and Novo Nordisk.

intensifying the company’s race with Novo Nordisk to develop longer-acting insulins. Lilly’s once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily ...

If you’re on the fence about investing in Eli Lilly And Co or Novo Nordisk A/S (ADR) because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

It has initiated a mid-stage trial in combination with Lilly's Zepbound and plans to initiate a second such trial with Novo Nordisk's ... $170 million in a funding round led by life sciences ...

Bengaluru: Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 ...

All dos­es of No­vo Nordisk’s Ozem­pic are ex­pect­ed to face “in­ter­mit­tent short­ages” in Eu­rope dur­ing the fourth quar­ter of the year, es­pe­cial­ly low­er dos­es, ...

It has initiated a mid-stage trial in combination with Lilly's Zepbound and plans to initiate a second such trial with Novo Nordisk's Wegovy in the first half of 2025. The proposed IPO comes months ...